390 related articles for article (PubMed ID: 23076151)
41. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
[TBL] [Abstract][Full Text] [Related]
42. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
43. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
44. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
45. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
46. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
[TBL] [Abstract][Full Text] [Related]
47. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.
Vido MJ; Le K; Hartsough EJ; Aplin AE
Cell Rep; 2018 Nov; 25(6):1501-1510.e3. PubMed ID: 30404005
[TBL] [Abstract][Full Text] [Related]
48. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
49. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
[TBL] [Abstract][Full Text] [Related]
50. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Goetz EM; Ghandi M; Treacy DJ; Wagle N; Garraway LA
Cancer Res; 2014 Dec; 74(23):7079-89. PubMed ID: 25320010
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
52. Spatial control of Shoc2-scaffold-mediated ERK1/2 signaling requires remodeling activity of the ATPase PSMC5.
Jang ER; Jang H; Shi P; Popa G; Jeoung M; Galperin E
J Cell Sci; 2015 Dec; 128(23):4428-41. PubMed ID: 26519477
[TBL] [Abstract][Full Text] [Related]
53. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
54. The MAPK pathway as an apoptosis enhancer in melanoma.
Haydn JM; Hufnagel A; Grimm J; Maurus K; Schartl M; Meierjohann S
Oncotarget; 2014 Jul; 5(13):5040-53. PubMed ID: 24970815
[TBL] [Abstract][Full Text] [Related]
55. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
[TBL] [Abstract][Full Text] [Related]
56. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
Perna D; Karreth FA; Rust AG; Perez-Mancera PA; Rashid M; Iorio F; Alifrangis C; Arends MJ; Bosenberg MW; Bollag G; Tuveson DA; Adams DJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E536-45. PubMed ID: 25624498
[TBL] [Abstract][Full Text] [Related]
57. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
58. BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.
Kemper K; Krijgsman O; Kong X; Cornelissen-Steijger P; Shahrabi A; Weeber F; van der Velden DL; Bleijerveld OB; Kuilman T; Kluin RJC; Sun C; Voest EE; Ju YS; Schumacher TNM; Altelaar AFM; McDermott U; Adams DJ; Blank CU; Haanen JB; Peeper DS
Cell Rep; 2016 Jun; 16(1):263-277. PubMed ID: 27320919
[TBL] [Abstract][Full Text] [Related]
59. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
60. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT
Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]